Weekly round-up – what are members discussing?
Today, I highlight an interesting idea - to re-name of one of the steps in the cancer-immunity cycle. Plus, other questions posed by community members.
As cancer immunotherapy is a rapidly evolving field of research, keeping the framework up to date – improving on what’s included and adding new data when it gets published - will only be achieved through a collective effort from everyone involved. So it’s great to see members actively getting involved, contributing their ideas and provoking discussion within the community!
Dr Abhishek Garg, who was profiled recently in a member Q&A post, makes an interesting suggestion about renaming step 1 in the cancer-immunity cycle:
"Release of cancer-cell antigens" is a specific event with several exceptions. It may be renamed as "Exhibition of cancer-cell antigens" to be broad," he says.
You can read his post to find out more about why he thinks this is a good idea, and also the response of Dr Zoltan Fehervari, Senior Editor at Nature Research. Do you have any thoughts to add on this topic? – please join in the thread and contribute your ideas.
I’d like to also highlight some of the questions and ideas on the framework posed by other members, which we need your help to answer:
- On step 7, on the anti-BCL2 family members factors, Jose asks:
"What criteria drive the selection of a cell-death pathway in immunotherapy?"
- On step 5, chemokines, Veronika asks:
"How come chemokines are noted down with negative effects? The CXCR3/CXCR3 ligand axis, for instance, has been shown to recruit T and NK cells into tumors in mouse studies and has been associated with T cell infiltration in several human studies."
- On step 7, Killing of cancer cells, Saman suggests:
“We probably need to add a clinical response section to the map of cancer immunity and add factors that are shown to be predictive of response to IO”
Are you an expert on these topics – if so, please join in the discussion and add your thoughts.
Don’t be shy - please go to the website (on a computer rather than mobile) and add to or comment on the interactive framework. All contributions are welcome, no matter how big or small!
Please see our ‘how to’ post if you need a quick reminder about what you need to do.